Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).
Jiangsu Hengrui Pharmaceuticals reported that all resolutions at its 2025 annual general meeting on April 16, 2026, were approved by poll, confirming shareholder support for the company’s proposed corporate actions. The meeting covered matters including cash dividend distribution, director appointments for the tenth board session, the retirement of an independent non-executive director, the election of the board chairman and deputy chairman, senior management appointments, and changes in board committee composition.
The announcement specifies that a significant block of treasury A shares held in the company’s repurchase account carried no voting rights at the meeting, and that related parties, including Jiangsu Hengrui Pharmaceutical Group Co., Ltd., abstained from voting on resolutions tied to 2025 remuneration and liability insurance for directors and senior management. These governance steps underscore compliance with corporate governance standards and clarify the voting base, offering transparency for investors on how key decisions about leadership, pay, and oversight were approved.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong, engaged in the research, development, manufacturing, and sale of innovative and generic drugs. The group serves both domestic and international markets, focusing on therapeutic areas such as oncology and other high-value specialty treatments to strengthen its position in the global healthcare industry.
Average Trading Volume: 3,291,704
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$438.2B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.